ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,738.52
-1.78%
Dow Jones
42,579.08
-0.99%
US Dollar vs MXN
20.2897
0.04%
Brent Oil
69.34
0.00%
Bitcoin
87,612.74
-2.58%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Arvinas Inc (ARVN) Cotización

Arvinas Inc

Arvinas Inc (ARVN)

NASDAQ
18.06
0.565
(3.23%)
Cerrado 06 Marzo 3:00PM
Delayed by 15 minutes
18.05
-0.01
(-0.06%)
Fuera de horario: 4:50PM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
18.05
Postura de Compra
18.00
Postura de Venta
19.17
Volume Operado de la Acción
1,488,391
16.97 Rango del Día 18.93
15.53 Rango de 52 semanas 49.76
Capitalización de Mercado [m]
1.241B
Precio Anterior
17.495
Precio de Apertura
17.13
Hora
30
@
18.05
Última hora de negociación
Volumen financiero
US$ 26,758,204
Precio Promedio Ponderado
17.9779
Volumen promedio (3 m)
1,089,815
Acciones en circulación
68,771,867
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-6.25
Beneficio por acción (BPA)
-2.89
turnover
263.4M
Beneficio neto
-198.9M

Acerca de Arvinas Inc

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.arvinas.com
Sede
Wilmington, Delaware, USA
Fundado
-
Arvinas Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARVN. The last closing price for Arvinas was US$17.50. Over the last year, Arvinas shares have traded in a share price range of US$ 15.53 to US$ 49.76.

Arvinas currently has 68,771,867 shares in issue. The market capitalisation of Arvinas is US$1.20 billion. Arvinas has a price to earnings ratio (PE ratio) of -6.25.

Flujo de Opciones Arvinas (ARVN)

Ver flujo de opciones completo

Flujo General

Optimista

Prima Neta

957k

Calls / Puts

100.00%

Comp. / Vent.

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ARVN Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 Febrero 2025
ARVN (3.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 Febrero 2025
ARVN (3.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 Febrero 2025
ARVN (3.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 Febrero 2025
ARVN (3.23%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
24 Febrero 2025
ARVN (3.23%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
24 Febrero 2025
ARVN (3.23%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
24 Febrero 2025
ARVN (3.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 Febrero 2025
ARVN (3.23%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
18 Febrero 2025
ARVN (3.23%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.95.2478134110817.1518.615.53118610317.00947299CS
4-1.59-8.0957230142619.6420.376215.53130029617.75701875CS
12-4.18-18.803418803422.2322.479915.53108981518.27547296CS
26-7-27.944111776425.0529.610615.5380960421.2088638CS
52-29.52-62.055917595147.5749.7615.5377626726.21511255CS
156-46.89-72.205112411564.9475.389913.5760126332.33172166CS
260-31.84-63.820404890849.89108.46513.5757790742.90766702CS

ARVN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Arvinas?
El precio actual de las acciones de Arvinas es US$ 18.05
¿Cuántas acciones de Arvinas están en circulación?
Arvinas tiene 68,771,867 acciones en circulación
¿Cuál es la capitalización de mercado de Arvinas?
La capitalización de mercado de Arvinas es USD 1.2B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Arvinas?
Arvinas ha negociado en un rango de US$ 15.53 a US$ 49.76 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Arvinas?
El ratio precio/beneficio de Arvinas es -6.25
¿Cuál es el ratio de efectivo a ventas de Arvinas?
El ratio de efectivo a ventas de Arvinas es 4.72
¿Cuál es la moneda de reporte de Arvinas?
Arvinas presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Arvinas?
El último ingresos anual de Arvinas es USD 263.4M
¿Cuál es el último beneficio anual de Arvinas?
El último beneficio anual de Arvinas es USD -198.9M
¿Cuál es la dirección registrada de Arvinas?
La dirección registrada de Arvinas es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Arvinas?
La dirección del sitio web de Arvinas es www.arvinas.com
¿En qué sector industrial opera Arvinas?
Arvinas opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
PSTVPlus Therapeutics Inc
US$ 1.46
(317.14%)
359.59M
AGMHAGM Group Holdings Inc
US$ 0.213
(108.21%)
694.71M
LZMHLZ Technology Holdings Ltd
US$ 9.79
(33.56%)
590.5k
TNXPTonix Pharmaceuticals Holding Corporation
US$ 14.62
(33.39%)
16.07M
GVVisionary Holdings Inc
US$ 4.89
(32.34%)
135.24M
BLNEEastside Distilling Inc
US$ 0.7846
(-89.40%)
12.25k
ACONAclarion Inc
US$ 1.5501
(-77.86%)
51.53M
ELABPMGC Holdings Inc
US$ 0.7132
(-42.02%)
1.51M
SNBRSleep Number Corporation
US$ 7.49
(-41.89%)
4.56M
CCLDCareCloud Inc
US$ 2.0904
(-33.00%)
1.23M
AGMHAGM Group Holdings Inc
US$ 0.213
(108.21%)
694.71M
PSTVPlus Therapeutics Inc
US$ 1.46
(317.14%)
359.59M
NVDANVIDIA Corporation
US$ 110.57
(-5.74%)
321.25M
GVVisionary Holdings Inc
US$ 4.89
(32.34%)
135.24M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.75
(-11.38%)
134.95M

ARVN Discussion

Ver más
Mr.Mister Mr.Mister 1 día hace
Data imminent
👍️0
Monksdream Monksdream 6 meses hace
ARVN at a bottom channel
👍️0
Monksdream Monksdream 1 año hace
ARVN new 52=week high
👍️0
Monksdream Monksdream 1 año hace
ARVN new 52 week high
👍️0
Monksdream Monksdream 1 año hace
ARVN new 52 week high
👍️0
Monksdream Monksdream 1 año hace
ARVN new 52 week high
👍️0
crudeoil24 crudeoil24 4 años hace
ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”
👍️0
biocqr biocqr 5 años hace
Advantages of PROTACs vs. inhibition...

message_id=152832655
👍️0
G-lupo G-lupo 5 años hace
Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25
👍️0
boo boo boo boo 5 años hace
Starting to see a chink in the armor!
👍️0
G-lupo G-lupo 5 años hace
Possibly wall at 30.50
👍️0
G-lupo G-lupo 5 años hace
I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price
👍️0
boo boo boo boo 5 años hace
The offering:

8-k
👍️0
boo boo boo boo 5 años hace
Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!
👍️0
boo boo boo boo 5 años hace
It doesn't have to be a PR:

#8
👍️0
G-lupo G-lupo 5 años hace
Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30
👍️0
boo boo boo boo 5 años hace
https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/
👍️0
G-lupo G-lupo 5 años hace
When did they Do a price target announcement? I didn’t see that.
👍️0
boo boo boo boo 5 años hace
If I were in this one (I'm not), I'd be finding the exit on the price target announcement.
👍️0
G-lupo G-lupo 5 años hace
Arvn looking good, defintely see $26-27
👍️0
G-lupo G-lupo 5 años hace
What you mean IBD?
👍️0
boo boo boo boo 5 años hace
Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...
👍️0
G-lupo G-lupo 5 años hace
I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul
👍️0
boo boo boo boo 5 años hace
Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.
👍️0
G-lupo G-lupo 5 años hace
What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60
👍️0
boo boo boo boo 5 años hace
Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!
👍️0
boo boo boo boo 5 años hace
Fook R's!

EOM
👍️0
boo boo boo boo 5 años hace
Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!
👍️0
PennyStock Alert PennyStock Alert 6 años hace
ARVN
👍️0
G-lupo G-lupo 6 años hace
This stock very volatile, no rhyme or reason why it’s been up and down.
👍️0
morokoy morokoy 6 años hace
Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/
👍️0

Su Consulta Reciente

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios